Why choose CYNOGEN for Vysis ALK?

When an oncologist is considering the application of a targeted therapeutic drug for a patient, it’s important to have reliable diagnostic test results. For NSCLC patients for whom the targeted drug XALKORI® may be appropriate, there is an FDA-approved companion diagnostic commercially known as Vysis ALK (Vysis ALK Break Apart FISH Probe), a FISH-based (fluorescence in situ hybridization) test manufactured by Abbott Molecular. CYNOGEN is an Abbott company.

 

Indications and Important Safety Information

 

Vysis ALK has these primary benefits:

  • The test accurately identifies all ALK gene rearrangements in NSCLC patients
  • Early FISH testing at diagnosis can assist physicians in determining appropriate ALK-directed therapy
  • Vysis ALK is the only FDA-approved ALK companion diagnostic validated in XALKORI® (crizotinib) clinical trials

 

The National Comprehensive Cancer Network (NCCN GUIDELINES™) recognizes the Vysis ALK Break Apart FISH Probe Kit (Vysis ALK) as a specifically designed method for diagnosing ALK-rearranged adenocarcinomas.1  Vysis ALK provides reliable information to oncologists that can aid in the appropriate application of ALK-directed therapy.

 

Vysis ALK is intended for all NSCLC tissue specimens, including not otherwise specified (NOS) specimens.

 

 

In addition to Vysis ALK, CYNOGEN through its laboratory collaboration with PLUS Diagnostics offers a range of other lung cancer molecular tests. (These tests were developed and performance characteristics determined by PLUS Diagnostics. These tests have not been cleared or approved by the FDA.)

 

 

To Order Lung Cancer Tests 

To View Specimen Collection and Shipping Instructions

 

 

Intended Use

The Vysis ALK Break Apart FISH Probe Kit is a qualitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue specimens to aid in identifying those patients eligible for treatment with XALKORI® (crizotinib).

The test is for prescription use only.

 

Limitations of the Procedure

  • FOR IN VITRO DIAGNOSTIC USE ONLY.
  • Optimal performance of this test requires appropriate specimen handling, preparation, and storage as described in the instructions for use.
  • The Vysis ALK Break Apart FISH Probe Kit has been optimized only for identifying and quantifying rearrangements of the ALK gene from formalin-fixed, paraffin-embedded human NSCLC tissue specimens. The assay should be performed only on 10% neutral buffered formalin FFPE human lung cancer tissue. Other types of specimens or fixatives should not be used.
  • The performance of the Vysis ALK Break Apart FISH Probe Kit was established using the procedures provided in the assay package insert only. Modifications to the procedures may alter the performance of the assay.
  • The clinical interpretation of any test results should be evaluated within the context of the patient’s medical history and other diagnostic laboratory test results.
  • FISH assay results may not be informative if the specimen quality and/or specimen slide preparation is inadequate.
  • Technologists performing the FISH signal enumeration must be capable of visually distinguishing between the orange, green, and yellow signals.

 

Caution

United States Federal law restricts this device to sale and distribution to or on the order of a physician or to a clinical laboratory; and use is restricted to, by, or on the order of a physician.

 

XALKORI® is a registered trademark of Pfizer Inc.

 

View our Vysis ALK brochure here.

 

 

 

References:

1. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) Non-Small Cell Lung Cancer (Version 1.2012). ©2011 National Comprehensive Cancer Network, Inc. Available at http://www.ncn.org.